Association of *SAPAP3* allelic variants with symptom dimensions and pharmacological treatment response in obsessive-compulsive disorder

Safoora Naaz,^{1,2^}

Srinivas Balachander,^{2,3^},

Nithyananda Srinivasa Murthy,³

Bhagyalakshmi MS,¹

Reeteka Sud,²

Priyanka Saha,¹

Janardhanan C Narayanaswamy,^{2,3}

Janardhan Reddy YC,^{2,3}

Sanjeev Jain,^{1,2}

Meera Purushottam,^{1,2}

Biju Viswanath^{1,2*}

^Equal contribution

¹ - Molecular Genetics Laboratory, Department of Psychiatry;

² - Accelerator Program for Discovery in Brain disorders using Stem cells (ADBS)

Laboratory, Department of Psychiatry;

³ - Obsessive-Compulsive Disorder Clinic, Department of Psychiatry;

National Institute of Mental Health & Neuro Sciences (NIMHANS), Bangalore

Corresponding Author – Dr. Biju Viswanath, Department of Psychiatry, NIMHANS, Hombegowda Nagar, Bangalore, India – 560029; Email: bijuv1@gmail.com; Phone: +919480829594

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract:

Background: Though several *SAPAP3* gene knockout studies in mice have implicated its role in compulsivity, human studies have failed to demonstrate its association with obsessive-compulsive disorder (OCD). We examined the association between allelic variants of a single nucleotide polymorphism in the *SAPAP3* gene (rs6662980) with specific aspects of the OCD phenotype.

Methods: A total of 200 subjects with OCD were genotyped using the TaqMan assay. All subjects were assessed using Mini International Neuropsychiatric Interview, the Yale-Brown Obsessive-Compulsive Scale, and their treatment response was evaluated over naturalistic treatment and follow-up.

Results: After correcting for multiple comparisons, G- allele at rs6662980 was found to be associated with contamination/washing symptoms ($p=0.003$). Logistic regression analysis also showed that presence of G allele predicted poor response to serotonin reuptake inhibitors [odds ratio = 2.473 (95% CI = 1.157 - 5.407), $p=0.021$]. Interaction between presence of G-allele and contamination factor score predicted SRI resistance ($B= 1.197$, $p = 0.006$).

Limitations: We did not use a dimensional measure for assessing OCD symptoms. Treatment response was assessed over naturalistic follow-up.

Conclusion: Specific phenotypic manifestations of OCD, which include contamination and washing-related symptoms along with resistance to serotonin reuptake inhibitors, may be related to alterations in the *SAPAP3* gene.

Keywords: obsessive-compulsive, *SAPAP3*, *DLGAP3*, treatment response

Public Significance Statement:

“This study finds that a specific polymorphism in the *SAPAP3* gene, was found to be associated with the contamination/washing symptoms of OCD and was also found to predict resistance to pharmacological treatment”

Highlights:

- *SAPAP3* gene is implicated in OCD
- Association of *SAPAP3* gene (rs6662980) with OCD phenotypes was examined
- Presence of the minor (G) allele predicted contamination & washing symptoms
- *SAPAP3* polymorphism had a significant association with treatment response
- Interaction between presence of G-allele and contamination factor score predicted treatment resistance

Disclosures & Acknowledgements:

Disclosures/Potential Conflicts of Interest: Nil

Funding/Support: This study has been supported by various research grants from Department of Biotechnology, Department of Science & Technology and the Indian Council Medical Research, Ministry of Health & Family Welfare, Government of India. SN, SB and RS are funded by the Accelerator program for Discovery in Brain disorders in Stem cells, a joint venture of the Department of Biotechnology. Government of India and the Pratiksha trust.

Acknowledgements: Nil

1. Introduction:

Obsessive-compulsive disorder (OCD) is a severe, chronic and debilitating neuropsychiatric disorder, that affects ~2 % of the world population (Ruscio et al., 2010). OCD has a strong genetic basis, with heritability estimates ranging from 27-47% (adult-onset) to 45-65% (childhood-onset) (Van Grootheest et al., 2007). Several candidate-gene and genome-wide association studies in OCD have implicated the role of genes in serotonergic, dopaminergic and glutamatergic systems. However, very few of these findings have been consistently replicated. (Pauls et al., 2014).

Neuroimaging, genetic and neurochemical evidence, as well as insights from animal models, suggest that glutamatergic signaling is dysregulated in OCD (Pittenger et al., 2011). Many genes in the glutamatergic system like *GRIN2B*, *SAPAP3* and *SLC1A1* have been associated with OCD (Pauls, 2010). Pharmacologic agents modulating glutamatergic transmission such as memantine, topiramate and riluzole have shown some promise in the treatment of OCD (Grados et al., 2013). Further, glutamatergic function is also altered by serotonin reuptake inhibitors (SRIs), which are the first line treatment for OCD (Ohno, 2018; Rodrigues et al., 2015).

Mice with mutated versions of *SAPAP3*, (also *DLGAP3*) exhibit OCD-like behavior, including excessive grooming, increased anxiety and abnormal cortico-striatal neurotransmission which was significantly reduced after Fluoxetine treatment (Burguière et al., 2013; Manning et al., 2019; Welch et al., 2007). *SAPAP3* belongs to highly homologous *SAPAP* family proteins, which are components of the post-synaptic density that interact with multiple members of proteins from PSD95- and SHANK-families, to form a postsynaptic

scaffolding complex, which plays an important role in facilitating organization of post synaptic signaling at the glutamatergic synapse (Scannevin and Huganir, 2000).

SAPAP3, the only member which is highly expressed in the striatum, has been studied in OCD spectrum disorders. A family-based association study showed *SAPAP3* as a promising functional candidate gene for human grooming disorder (Boardman et al., 2011). Another case-control study supports the role of *SAPAP3* in Trichotillomania (TTM) and OCD (Züchner et al., 2009). As OCD is a heterogeneous disorder, it may be important to study the association of its specific phenotypic manifestations with genetic factors. A study in the South African population links *SAPAP3* variants to the development of early onset OCD (Boardman et al., 2011).

Despite several replications in mice models which have shown *SAPAP3* to be associated with compulsive behaviors, none of the human genome-wide studies done in OCD have been able to detect significant SNPs in this region. The previously mentioned family-based candidate gene study (Bienvenu et al., 2009) which examined multiple SNPs within the *SAPAP3* gene found the presence of G allele in rs6662980 to be nominally associated with Grooming Disorders (relative risk = 1.6). In the db-SNP database, the minor allele frequency of this variant in South Asian populations is reported to be 0.21 (1000Genomes) and 0.23 (PAGE) (Sherry et al., 2001). In this current study, we examine the association between clinical characteristics of OCD (symptom dimensions, disease severity, age at onset, comorbidity, treatment response) and an SNP in the *SAPAP3* gene (rs6662980 in chromosome 1p35).

2. Materials & Methods:

2.1. Samples:

Two hundred subjects diagnosed with OCD by DSM IV – TR (APA – DSM, 2000) were identified at a specialty OCD clinic in south India at the National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru and invited to participate after due informed consent. The study was approved by the NIMHANS ethics committee.

Patients were assessed on a detailed clinical proforma employed in the OCD clinic which includes socio-demographic data, age of onset of OCD, duration of illness, duration of untreated illness, detailed history of present illness, presence of common comorbid disorders — including mood disorders, anxiety disorders, tic disorders and other OC spectrum disorders, family history of OCD and major psychiatric disorders, and treatment details. Patients were, in addition, assessed on Yale Brown Obsessive Compulsive Scale (YBOCS) (Goodman et al., 1989b, 1989a), Mini International Neuropsychiatric Interview plus (MINI plus) (Sheehan et al., 1998), and the Clinical Global Impression scale (CGI) (Guy, 1976). Insight was measured using YBOCS item 11 (Goodman et al., 1989a). Diagnosis and associated features were independently confirmed by two clinicians, one of them being a consultant psychiatrist with experience in evaluating persons with OCD. Patients with comorbid psychosis, bipolar disorder and mental retardation were excluded from the study.

Patients underwent routine clinical treatment and follow-up at the OCD clinic. All received pharmacological treatment, which was based on existing standard guidelines (Janardhan Reddy et al., 2017; Koran et al., 2007). Serotonin reuptake inhibitor (SRI) response was defined as reduction of YBOCS $> 35\%$ and CGI-I score of 1 or 2 after 12 weeks of treatment (Mataix-Cols et al., 2016). SRI non-responder was defined as reduction of YBOCS $< 25\%$ even after 12 weeks of treatment at adequate dose of SRI and CGI-I of 3 and above with, at least two SRIs (Math and Janardhan Reddy, 2007; Pallanti et al., 2002; Shetti et al., 2005).

Patients who were partial responders, and who received inadequate trials were excluded from the pharmaco-genetic analysis.

2.2 Genotyping:

Eight milliliters blood was drawn from the study subjects under aseptic precautions. DNA was extracted using standard techniques (Miller et al., 1988). Genotyping analysis at rs6662980 was done using a commercially available Taqman genotyping assay (Applied Biosystems, assay ID Number 186966013_1). The polymerase chain reaction (PCR) for the Taqman SNP genotyping was carried out as per the manufacturer's specifications.

2.3. Statistical analysis:

Fourteen symptom categories of the Y-BOCS checklist (excluding miscellaneous symptoms) were used to generate factors (symptom dimensions). Principal component analysis was performed with 'varimax' rotation and an eigenvalue greater than 1 was used to select the number of factors. Factor loadings of greater than 0.50 were considered robust. Univariate analysis of clinical variables (YBOCS total score, insight score, treatment response and the scores obtained on five dimensions) were assessed for genotype association using t-test and chi-square (Fisher's exact) tests. The Benjamini-Hochberg procedure for false-discovery rate (FDR) correction was used to correct for multiple comparisons. To look for predictors of treatment response, logistic regression was used. The predictor variables included key clinical variables (including age, sex, YBOCS and the factor scores as covariates) and the presence or absence of A/G allele. All analyses were performed using R version 3.6.1.

3. Results:

Sample Description:

Table 1 shows the clinical and socio-demographic characteristics of the 200 subjects who were included in this study. Of these, 79 were found to have inadequate (<25% reduction in YBOCS or CGI-I>3) response to at least 2 SRI trials on follow-up (median duration = 60 months). Another 98 subjects were found to have adequate response (>35% YBOCS reduction or CGI-I<3) to an SRI treatment. Two subjects were excluded due to lack of follow-up (dropped out of follow-up after initial evaluation), 20 showed partial response (25-35% reduction in YBOCS and CGI-I=3) after one or more SRI trials. Thus for the purpose of comparing the influence of the *SAPAP3* genotype on the response to SRIs, only 177 patients who met the criterion for either response or resistance, were included.

Results of the factor analysis

Items in YBOCS checklist which had <10% occurrence in the data were excluded from the factor analysis viz somatic obsessions, counting compulsions, and miscellaneous obsessions and compulsions. Using principal component analysis with “varimax” rotation, 5 factors with eigenvalue > 1.0 were extracted. The loadings in each factor were as follows: symmetry (0.97) and ordering/arranging (0.85) in Factor 1, contamination (0.99) and washing (0.95) in Factor 2, pathological doubts (0.76) and checking (0.98) in Factor 3, aggressive (0.53), sexual (0.63) and religious (0.60) with mental compulsions (0.72) in Factor 4, and hoarding obsessions (0.90) with collecting compulsions (0.97) in Factor 5. The overall model could explain 74% of the total variance.

Distribution of allelic variants of *SAPAP3*

The Hardy-Weinberg equilibrium was tested and found to have no deviation (Chi-Sq= 1.048, $p=0.39$). The most common genotype was AA, seen in 148 (74%) of the study population. Both the AG (46/200) and the GG genotypes (6/200) accounted for a total of 26% of the study sample. Hence, we compared those subjects that were AA homozygous ($n=148$) to those having at least one G allele ($n=52$), for the association analysis of *SAPAP3* genotype with the OCD phenotype.

Association with clinical variables

Table 2 shows the results of the univariate analysis. Significantly more contamination obsessions ($p=0.008$) and washing compulsions ($p=0.009$) were seen in the G allele carrier group. Using the contamination washing factor score as a continuous measure, a higher score was found in the G allele carrier group ($p=0.003$). Additionally, a greater proportion of Generalized Anxiety Disorder was seen in those with the AA genotype (or G non carriers) ($p=0.007$). When the Benjamini-Hochberg procedure was applied with an FDR of 0.10, only contamination/washing was found to survive the correction for significance.

Association with treatment response

In the univariate analysis shown in Table 2, the G allele carrier group was found to have a greater proportion of SRI-non-responders ($p=0.03$) and had also received greater number of SRI trials ($p=0.017$). Table 3 shows the results of multiple regression model, in which we examined predictors of SRI resistance in present group of OCD patients. Prediction accuracy of the overall logistic regression model was 64.7%. We also observed an interaction between presence of G-allele and contamination factor score to predict SRI resistance ($B= 1.197$, $p = 0.00573$) (see Figure 1).

Discussion:

The current study examined the allelic variants at rs6662980 within *SAPAP3* gene, in a sample of 200 subjects with OCD; and association with clinical characteristics of OCD, including symptom dimensions and treatment response. The two key findings in the study were that the G-allele at this SNP was associated with contamination/washing symptom dimension, and with poor response to treatment with SRIs.

In our study sample, more than one-third of the participants had familial OCD. There was also a greater proportion of those with juvenile onset. Previous studies have found that familial OCD is also associated with more compulsions, greater severity of illness and greater comorbidity (Arumugham et al., 2014; Viswanath et al., 2011). The other characteristics of the sample (symptoms, comorbidity, treatment response) are as in other OCD studies from our center (Taj M J et al., 2018, 2013).

The G allele was found to be associated with the contamination/washing symptom dimension. In light of the evidence from animal models showing excess grooming behaviors after knockout of the gene (Welch et al., 2007), previous studies on *SAPAP3* in humans have specifically examined its relationship with trichotillomania & skin picking disorder (Boardman et al., 2011; Züchner et al., 2009). In our sample, we found only a few subjects with comorbid trichotillomania/skin picking disorder, and hence the association could not be tested. The association between variants in the *SAPAP3* gene and contamination/washing symptoms in our study makes us speculate whether animal grooming behaviors might be analogous to human cleaning/washing behavior, in addition to trichotillomania/skin picking (Ahmari, 2016; Kalueff et al., 2016). Cross-cultural studies on contamination measures have found cleanliness and grooming to co-exist in factor analysis, specifically in non-European samples (Williams and Turkheimer, 2007).

With regards to treatment response, the G allele was found to be associated with SRI treatment resistance. Excessive grooming behaviors observed in *SAPAP3* knockout mice has however been shown to be rescued after treatment with serotonin reuptake inhibitors (Burguière et al., 2013; Welch et al., 2007). Several previous studies have examined the influence of genes on the response to SRIs. A large GWAS which examined treatment response in OCD (Qin et al., 2016), found a locus in *DLGAP1* and multiple other genes in the glutamatergic signaling pathway (Enrichment score = 3.38, FDR=0.00097) to be associated with SRI resistance. Two studies with a candidate gene approach that have examined the association between *SLC1A1* SNPs and treatment response (Abdolhosseinzadeh et al., 2019; Real et al., 2013) have also found an association with treatment resistance. Recently, a study using a polygenic risk score with all the above-mentioned variants (Alemany-Navarro et al., 2019) failed to find any association between the composite score and treatment response in OCD. However, they did not include variants in the *SAPAP3* gene for their estimation of the polygenic risk score.

A key strength of our study includes the use of structured clinical assessments to characterize symptoms, comorbidities and treatment resistance. The use of dimensional-YBOCS (DYBOCS) (Rosario-Campos et al., 2006) ratings could have helped better delineate the phenotype of OCD symptoms, rather than using scores derived from a factor-analysis of the YBOCS checklist. We also assessed treatment response over a naturalistic follow-up, and did not examine response or the lack thereof to specific SRIs. The exclusion of partial responders from our analysis, as we chose to specifically compare “resistant” OCD with responders, could be an additional limitation. Considering that we looked for the association of various phenotypes within OCD (five symptoms dimensions, early- vs adult-onset, comorbidity and treatment response), the sample size of 200 may have been suboptimal. Another limitation is

that we did not genotype ancestry informative markers to rule out any effects of population stratification in this study. We have done this previously in another study of OCD from our center and did not find any stratification (Taj et al. 2013).

To conclude, *SAPAP3* rs6662980 genotype was associated with contamination dimension of OCD and SRI treatment resistance in this study. This finding needs to be confirmed in larger genome-wide pharmacogenetic studies (Antypa et al., 2014; Jung et al., 2017) in this population.

References:

- Abdolhosseinzadeh, S., Sina, M., Ahmadiani, A., Asadi, S., Shams, J. (2019). Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder. *J Clin Pharm Ther* 44, 39–48. <https://doi.org/10.1111/jcpt.12766>
- Ahmari, S.E. (2016). Using mice to model Obsessive Compulsive Disorder: From genes to circuits. *Neuroscience* 321, 121–137. <https://doi.org/10.1016/j.neuroscience.2015.11.009>
- Alemaný-Navarro, M., Costas, J., Real, E., Segalàs, C., Bertolín, S., Domènech, L., Rabionet, R., Carracedo, Á., Menchón, J.M., Alonso, P. (2019). Do polygenic risk and stressful life events predict pharmacological treatment response in obsessive compulsive disorder? A gene-environment interaction approach. *Transl Psychiatry* 9, 70. <https://doi.org/10.1038/s41398-019-0410-0>
- Antypa, N., Drago, A., Serretti, A. (2014). Genomewide interaction and enrichment analysis on antidepressant response. *Psychol Med* 44, 753–765. <https://doi.org/10.1017/S0033291713001554>
- Arumugham, S.S., Cherian, A.V., Baruah, U., Viswanath, B., Narayanaswamy, J.C., Math, S.B., Reddy, Y.C.J. (2014). Comparison of clinical characteristics of familial and sporadic obsessive-compulsive disorder. *Compr Psychiatry* 55, 1520–1525. <https://doi.org/10.1016/j.comppsy.2014.07.006>
- Bienvenu, O.J., Wang, Y., Shugart, Y.Y., Welch, J.M., Grados, M.A., Fyer, A.J., Rauch, S.L., McCracken, J.T., Rasmussen, S.A., Murphy, D.L., Cullen, B., Valle, D., Hoehn-Saric, R., Greenberg, B.D., Pinto, A., Knowles, J.A., Piacentini, J., Pauls, D.L., Liang, K.Y., Willour, V.L., Riddle, M., Samuels, J.F., Feng, G., Nestadt, G. (2009). Sapap3 and pathological grooming in humans: Results from the OCD collaborative genetics study. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 150B, 710–720. <https://doi.org/10.1002/ajmg.b.30897>
- Boardman, L., van der Merwe, L., Lochner, C., Kinnear, C.J., Seedat, S., Stein, D.J., Moolman-Smook, J.C., Hemmings, S.M.J. (2011). Investigating SAPAP3 variants in the etiology of obsessive-compulsive disorder and trichotillomania in the South

- African white population. *Compr Psychiatry* 52, 181–187. <https://doi.org/10.1016/j.comppsy.2010.05.007>
- Burguière, E., Monteiro, P., Feng, G., Graybiel, A.M. (2013). Optogenetic stimulation of lateral orbitofronto-striatal pathway suppresses compulsive behaviors. *Science* 340, 1243–1246. <https://doi.org/10.1126/science.1232380>
- Goodman, W.K., Price, L.H., Rasmussen, S.A., Mazure, C., Delgado, P., Heninger, G.R., Charney, D.S. (1989a). The Yale-Brown Obsessive Compulsive Scale. II. Validity. *Arch. Gen. Psychiatry* 46, 1012–1016.
- Goodman, W.K., Price, L.H., Rasmussen, S.A., Mazure, C., Fleischmann, R.L., Hill, C.L., Heninger, G.R., Charney, D.S. (1989b). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. *Arch. Gen. Psychiatry* 46, 1006–1011.
- Grados, M.A., Specht, M.W., Sung, H.-M., Fortune, D. (2013). Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach. *Expert Opin Drug Discov* 8, 1515–1527. <https://doi.org/10.1517/17460441.2013.845553>
- Guy, W. (1976). ECDEU assessment manual for psychopharmacology, in: ECDEU Assessment Manual for Psychopharmacology. U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rev. Rockville (MD).
- Janardhan Reddy, Y.C., Sundar, A.S., Narayanaswamy, J.C., Math, S.B. (2017). Clinical practice guidelines for Obsessive-Compulsive Disorder. *Indian J Psychiatry* 59, S74–S90. <https://doi.org/10.4103/0019-5545.196976>
- Jung, J., Tawa, E.A., Muench, C., Rosen, A.D., Rickels, K., Lohoff, F.W. (2017). Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder. *Psychiatry Res* 254, 8–11. <https://doi.org/10.1016/j.psychres.2017.04.025>
- Kalueff, A.V., Stewart, A.M., Song, C., Berridge, K.C., Graybiel, A.M., Fentress, J.C. (2016). Neurobiology of rodent self-grooming and its value for translational neuroscience. *Nat. Rev. Neurosci.* 17, 45–59. <https://doi.org/10.1038/nrn.2015.8>
- Koran, L.M., Hanna, G.L., Hollander, E., Nestadt, G., Simpson, H.B., American Psychiatric Association (2007). Practice guideline for the treatment of patients with obsessive-compulsive disorder. *Am J Psychiatry* 164, 5–53.

- Manning, E.E., Dombrovski, A.Y., Torregrossa, M.M., Ahmari, S.E. (2019). Impaired instrumental reversal learning is associated with increased medial prefrontal cortex activity in Sapap3 knockout mouse model of compulsive behavior. *Neuropsychopharmacology* 44, 1494–1504. <https://doi.org/10.1038/s41386-018-0307-2>
- Mataix-Cols, D., Fernández de la Cruz, Nordsletten, A.E., Lenhard, F., Isomura, K., Simpson, H.B. (2016). Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder. *World Psychiatry* 15, 80–81. <https://doi.org/10.1002/wps.20299>
- Math, S.B., Janardhan Reddy, Y.C. (2007). Issues in the pharmacological treatment of obsessive-compulsive disorder. *Int. J. Clin. Pract.* 61, 1188–1197. <https://doi.org/10.1111/j.1742-1241.2007.01356.x>
- Miller, S.A., Dykes, D.D., Polesky, H.F. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res.* 16, 1215. <https://doi.org/10.1093/nar/16.3.1215>
- Ohno, Y. (2018). Astrocytic Kir4.1 potassium channels as a novel therapeutic target for epilepsy and mood disorders. *Neural Regen Res* 13, 651–652. <https://doi.org/10.4103/1673-5374.230355>
- Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., Pato, M., Stein, D., Zohar, J. (2002). Treatment non-response in OCD: methodological issues and operational definitions. *Int J Neuropsychopharmacol* 5, 181–191. <https://doi.org/10.1017/S1461145702002900>
- Pauls, D.L. (2010). The genetics of obsessive-compulsive disorder: a review. *Dialogues Clin Neurosci* 12, 149–163.
- Pauls, D.L., Abramovitch, A., Rauch, S.L., Geller, D.A. (2014). Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. *Nature Reviews Neuroscience* 15, 410–424. <https://doi.org/10.1038/nrn3746>
- Pittenger, C., Bloch, M.H., Williams, K. (2011). Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. *Pharmacol. Ther.* 132, 314–332. <https://doi.org/10.1016/j.pharmthera.2011.09.006>

- Qin, H., Samuels, J.F., Wang, Y., Zhu, Y., Grados, M.A., Riddle, M.A., Greenberg, B.D., Knowles, J.A., Fyer, A.J., McCracken, J.T., Murphy, D.L., Rasmussen, S.A., Cullen, B.A., Piacentini, J., Geller, D., Stewart, S.E., Pauls, D., Bienvenu, O.J., Goes, F.S., Maher, B., Pulver, A.E., Valle, D., Lange, C., Mattheisen, M., McLaughlin, N.C., Liang, K.-Y., Nurmi, E.L., Askland, K.D., Nestadt, G., Shugart, Y.Y. (2016). Whole-genome association analysis of treatment response in obsessive-compulsive disorder. *Mol. Psychiatry* 21, 270–276. <https://doi.org/10.1038/mp.2015.32>
- Real, E., Gratacòs, M., Labad, J., Alonso, P., Escaramís, G., Segalàs, C., Subirà, M., López-Solà, C., Estivill, X., Menchón, J.M. (2013). Interaction of SLC1A1 gene variants and life stress on pharmacological resistance in obsessive-compulsive disorder. *Pharmacogenomics J.* 13, 470–475. <https://doi.org/10.1038/tpj.2012.30>
- Rodrigues, D.O., Bristot, I.J., Klamt, F., Frizzo, M.E. (2015). Sertraline reduces glutamate uptake in human platelets. *Neurotoxicology* 51, 192–197. <https://doi.org/10.1016/j.neuro.2015.10.014>
- Rosario-Campos, M.C., Miguel, E.C., Quatrano, S., Chacon, P., Ferrao, Y., Findley, D., Katsovich, L., Scahill, L., King, R.A., Woody, S.R., Tolin, D., Hollander, E., Kano, Y., Leckman, J.F. (2006). The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions. *Mol. Psychiatry* 11, 495–504. <https://doi.org/10.1038/sj.mp.4001798>
- Ruscio, A.M., Stein, D.J., Chiu, W.T., Kessler, R.C. (2010). The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. *Mol. Psychiatry* 15, 53–63. <https://doi.org/10.1038/mp.2008.94>
- Scannevin, R.H., Huganir, R.L. (2000). Postsynaptic organization and regulation of excitatory synapses. *Nat. Rev. Neurosci.* 1, 133–141. <https://doi.org/10.1038/35039075>
- Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., Dunbar, G.C. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 59 Suppl 20, 22-33;quiz 34-57.

- Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M., Sirotkin, K. (2001). dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res.* 29, 308–311. <https://doi.org/10.1093/nar/29.1.308>
- Shetti, C.N., Reddy, Y.C.J., Kandavel, T., Kashyap, K., Singiseti, S., Hiremath, A.S., Siddequehusen, M.U.-F., Raghunandan, S. (2005). Clinical predictors of drug nonresponse in obsessive-compulsive disorder. *J Clin Psychiatry* 66, 1517–1523.
- Taj M J, R.J., Ganesh, S., Shukla, T., Deolankar, S., Nadella, R.K., Sen, S., Purushottam, M., Reddy, Y.C.J., Jain, S., Viswanath, B. (2018). BDNF gene and obsessive compulsive disorder risk, symptom dimensions and treatment response. *Asian J Psychiatr* 38, 65–69. <https://doi.org/10.1016/j.ajp.2017.10.014>
- Taj M J, R.J., Viswanath, B., Purushottam, M., Kandavel, T., Janardhan Reddy, Y.C., Jain, S. (2013). DRD4 gene and obsessive compulsive disorder: do symptom dimensions have specific genetic correlates? *Prog. Neuropsychopharmacol. Biol. Psychiatry* 41, 18–23. <https://doi.org/10.1016/j.pnpbp.2012.10.023>
- Van Grootheest, D.S., Cath, D.C., Beekman, A.T., Boomsma, D.I. (2007). Genetic and environmental influences on obsessive-compulsive symptoms in adults: a population-based twin-family study. *Psychol Med* 37, 1635–1644. <https://doi.org/10.1017/S0033291707000980>
- Viswanath, B., Narayanaswamy, J.C., Cherian, A.V., Reddy, Y.C.J., Math, S.B. (2011). Is familial obsessive-compulsive disorder different from sporadic obsessive-compulsive disorder? A comparison of clinical characteristics, comorbidity and treatment response. *Psychopathology* 44, 83–89. <https://doi.org/10.1159/000317776>
- Welch, J.M., Lu, J., Rodriguiz, R.M., Trotta, N.C., Peca, J., Ding, J.-D., Feliciano, C., Chen, M., Adams, J.P., Luo, J., Dudek, S.M., Weinberg, R.J., Calakos, N., Wetsel, W.C., Feng, G. (2007). Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. *Nature* 448, 894–900. <https://doi.org/10.1038/nature06104>
- Williams, M.T., Turkheimer, E. (2007). Identification and explanation of racial differences on contamination measures. *Behav Res Ther* 45, 3041–3050. <https://doi.org/10.1016/j.brat.2007.08.013>
- Züchner, S., Wendland, J.R., Ashley-Koch, A.E., Collins, A.L., Tran-Viet, K.N., Quinn, K., Timpano, K.C., Cuccaro, M.L., Pericak-Vance, M.A., Steffens, D.C., Krishnan, K.R.,

Feng, G., Murphy, D.L. (2009). Multiple rare SAPAP3 missense variants in trichotillomania and OCD. Mol. Psychiatry 14, 6–9. <https://doi.org/10.1038/mp.2008.83>

Tables & Figures:

Table 1 Clinical Characteristics of the Sample (N=200)

Characteristic		Mean (SD) or n (%)
Sex	Male	108 (54%)
	Female	92 (46%)
Age (years)		28.12 (10.41)
Age at Onset (years)		19.73 (7.86)
Juvenile Onset (<18)		100 (50%)
Duration of Illness (years)		8.38 (7.07) (Median=6.5)
YBOCS Total Score (Baseline)		25.79 (6.97)
CGI-S (Baseline)		4.51 (0.78)
Insight		1.29 (0.87)
Poor Insight		19 (9.5%)
YBOCS Checklist Obsessions (Lifetime)	Contamination	126 (63%)
	Somatic	12 (6%)
	Aggressive	65 (32.5%)
	Sexual	49 (24.5%)
	Religious	52 (26%)
	Hoarding	30 (15%)
	Pathological Doubts	104 (52%)
	Symmetry	64 (32%)
	Miscellaneous	31 (15.5%)
YBOCS Checklist Compulsions (Lifetime)	Washing	127 (63.5%)
	Checking	104 (52%)
	Repeating	76 (38%)
	Counting	22 (11%)
	Collecting	29 (14.5%)
	Ordering/Arranging	41 (20.5%)

		Miscellaneous	46 (23%)
		Mental Compulsions	44 (22%)
Comorbidities			
Major Depressive Disorder			72 (36%)
Dysthymia			8 (4%)
Suicidality	no risk		176 (88%)
	low risk		17 (8.5%)
	moderate risk		5 (2.5%)
	high risk		2 (1%)
Generalized Anxiety Disorder			30 (0.15)
Panic Disorder			10 (0.05)
Social Anxiety Disorder			8 (0.04)
Any Anxiety Disorder			43 (21.5%)
Tic Disorder/Tourette's Syndrome			10 (5%)
Body Dysmorphic Disorder			1 (0.5%)
Trichotillomania/Skin Picking			7 (3.5%)
Family History of Any Psychiatric Illness			105 (52.5%)
Family History of OCD (in FDR)			75 (37.5%)
Number of Failed Adequate SRI Trials			1.22 (1.49) (Median= 1; Range 0-6)
SRI Resistant (<25% reduction to at least 2 adequate SRI Trials) (n=177)			79 (44.6%)
Duration of follow-up at the OCD Clinic (in months)			65.88 (34.65) Median = 60

YBOCS – Yale Brown Obsessive-Compulsive Scale; CGI-S – Clinical Global Impression - Severity; SRI – Serotonin Reuptake Inhibitor; FDR – First-Degree Relative OCD – Obsessive-Compulsive Disorder

Table 2. Univariate Analyses of Clinical Characteristics between AA homozygous and G-allele carriers of the *SAPAP3* gene rs6662980 variants (N=200)

Characteristic	AA (n=148)	G Carrier (n=52)	t/ χ^2	p
Age (years)	27.89 (10.61)	28.79 (9.88)	-0.56	0.579
Sex (Males)	85 (57.43%)	23 (44%)	2.19	0.139
Age at onset (years)	19.61 (8.21)	20.08 (6.83)	-0.40	0.691
Juvenile Onset	76 (51.35%)	24 (46.15%)	0.23	0.629
YBOCS Total Score	25.27 (7.26)	27.25 (5.87)	-1.96	0.052
YBOCS Insight (Item-11)	1.3 (0.85)	1.27 (0.91)	0.19	0.846
Poor Insight (YBOCS Item 11 - 3 or 4)	13 (8.78%)	6 (12%)	0.09	0.76
CGI-S	4.47 (0.83)	4.63 (0.59)	-1.57	0.118
Contamination Obsessions	88 (59.46%)	42 (80.77%)	6.77	0.009
Somatic Obsessions	8 (5.41%)	4 (7.69%)	0.07	0.796
Aggressive Obsessions	51 (34.46%)	14 (26.92%)	0.68	0.409
Sexual Obsessions	37 (25%)	12 (23.08%)	0.01	0.928
Religious Obsessions	41 (27.7%)	11 (21.15%)	0.55	0.458
Hoarding Obsessions	21 (14.19%)	9 (17.31%)	0.10	0.752
Pathological Doubts	77 (52.03%)	27 (51.92%)	0.00	1.000
Need for Symmetry	47 (31.76%)	17 (32.69%)	0.00	1.000
Washing Compulsions	84 (56.75%)	41 (78.85%)	7.09	0.008
Checking Compulsions	79 (53.38%)	25 (48.08%)	0.25	0.619
Repeating Compulsions	57 (38.51%)	19 (36.54%)	0.01	0.931
Counting Compulsions	16 (10.81%)	6 (11.54%)	0.00	1.000
Collecting Compulsions	21 (14.19%)	8 (15.38%)	0.00	1.000
Ordering/Arranging Compulsions	27 (18.24%)	14 (26.92%)	1.29	0.257
Mental Rituals	28 (18.92%)	16 (30.77%)	2.50	0.114
Symptom dimensions				
Factor 1 (Symmetry & Arranging)	-0.05 (0.99)	0.13 (1.09)	-1.04	0.301

Factor 2 (Contamination & Washing)		-0.12 (1.04)	0.33 (0.85)	-3.07	0.003
Factor 3 (Taboo Thoughts, Cognitive Compulsions)		0.02 (1.02)	-0.05 (1.07)	0.38	0.707
Factor 4 (Pathological Doubts, Checking)		-0.02 (0.93)	0.04 (1.16)	-0.33	0.742
Factor 5 (Hoarding & Collecting)		0 (0.99)	0.01 (1.01)	-0.06	0.955
Family history					
Family History of any psychiatric illness		76 (51.35%)	26 (50%)	0.00	0.995
Family History of OCD (in FDR)		48 (32.43%)	19 (36.54%)	0.14	0.712
Comorbidity					
Major Depressive Disorder		57 (38.51%)	15 (28.85%)	1.17	0.280
Dysthymia		5 (3.38%)	3 (5.77%)	0.12	0.730
Suicidality	no risk	132 (89.19%)	44 (84.62%)	1.55	0.671
	low risk	11 (7.43%)	6 (11.54%)		
	moderate risk	4 (2.7%)	1 (1.92%)		
	high risk	1 (0.68%)	1 (1.92%)		
Generalized Anxiety Disorder		28 (18.92%)	2 (3.85%)	5.72 *	0.007
Panic Disorder		9 (6.08%)	1 (1.92%)	0.66 2	0.459
Social Anxiety Disorder		8 (5.41%)	0 (0%)	1.68 9	0.115
Agoraphobia		12 (8.11%)	5 (9.62%)	0.00 2	0.774
Body Dysmorphic Disorder		1 (0.68%)	0 (0%)	0.00	1.000
Tic Disorder		7 (4.73%)	3 (5.77%)	0.00	1.000
Motor Tics		7 (4.73%)	4 (7.69%)	0.20	0.651
Phonic Tics		3 (2.03%)	1 (1.92%)	0.00	1.000
Grooming Disorder (Trichotillomania/Excoriation)		6 (4.05%)	1 (1.92%)	0.08	0.779

Failed 2 or more adequate SRI Trials (n=177)	52 (35.14%)	27 (51.92%)	7.04	0.030
Number of failed adequate SRI Trials (n=197)	1.16 (1.43)	1.8 (1.52)	-2.45	0.017

YBOCS – Yale Brown Obsessive-Compulsive Scale; CGI-S – Clinical Global Impression - Severity; SRI – Serotonin Reuptake Inhibitor; FDR – First-Degree Relative OCD – Obsessive-Compulsive Disorder

Table 3. Logistic Regression to Predict Serotonin Reuptake Inhibitor Resistance (N=177)

Predictor Variable	B	SE	Odds Ratios (95% CI)	p
(Intercept)	-0.885	0.918	0.413 (0.066 - 2.466)	0.335
Age at onset of OCD	0.002	0.033	1.002 (0.941 - 1.07)	0.947
Age at Assessment (years)	-0.022	0.025	0.978 (0.929 - 1.025)	0.375
Sex (0=female, 1=male)	-0.056	0.361	0.946 (0.466 - 1.929)	0.878
YBOCS Total Score	0.045	0.026	1.046 (0.994 - 1.102)	0.087
Any Anxiety Disorder (0=no, 1=yes)	-0.463	0.403	0.629 (0.279 - 1.371)	0.251
Factor 1 (Symmetry & Arranging)	-0.054	0.187	0.948 (0.653 - 1.367)	0.774
Factor 2 (Contamination & Washing)	-0.391	0.180	0.676 (0.472 - 0.958)	0.030
Factor 3 (Taboo Thoughts, Mental Compulsions)	-0.218	0.172	0.804 (0.572 - 1.125)	0.205
Factor 4 (Pathological Doubts, Checking)	-0.108	0.173	0.898 (0.636 - 1.259)	0.533
Factor 5 (Hoarding & Collecting)	-0.074	0.194	0.928 (0.627 - 1.351)	0.701
Presence of G Allele (0=no, 1=yes)	0.905	0.392	2.473 (1.157 - 5.407)	0.021
Interaction Analysis				

Contamination/Washing Factor Score * Presence of G allele	1.296	0.455	3.654 (2.761 – 4.547)	0.004
---	-------	-------	-----------------------	--------------

YBOCS – Yale-Brown Obsessive-Compulsive Scale; OCD – Obsessive-Compulsive Disorder

Figure 1. Interaction plot showing differential relationship between contamination factor score and SRI treatment response with and without presence of the G allele in *SAPAP3* rs6662980

Explanation – In the presence of G allele, those with higher contamination/washing factor score are more likely to be SRI resistant; on the other hand, those with AA allelic variant with higher contamination/washing scores are less likely to have SRI resistance

SRI – Serotonin Reuptake Inhibitor